Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal

Deal Worth Up To $2.37bn

As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.

Biogen_Switzerland
Biogen's filing of aducanumab is the most anticipated biopharma sector event in 2020

Biogen Inc. is investing more in Alzheimer’s and Parkinson’s via a deal with Sangamo, paying $350m upfront to in-license preclinical candidates which use the zinc-finger protein (ZFP) technology to regulate genes.

The deal demonstrates Biogen’s focus on neuroscience, and Alzheimer’s in particular, where its imminent filing of aducanumab with the US...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip